Aurobindo Pharma gets USFDA nod for infection treatment drug
Team Udayavani, Jul 11, 2018, 4:24 PM IST
New Delhi: Drug firm Aurobindo Pharma has received final approval from the USFDA to manufacture and market Azithromycin tablets, used for the treatment of patients with mild to moderate infections, in the US market.
The approval has been granted in the strengths of 250 mg and 500 mg, and the product will be launched this month, Aurobindo Pharma said in a BSE filing.
The approved product is generic equivalent of Pfizer Inc’s Zithromax tablet, it added.
Quoting IQVIA sales data, the company said, the approved product has an estimated market size of USD 132 million for the 12 months ending May 2018.
Aurobindo Pharma currently has a total of 337 ANDA approvals (344 final approvals including 17 from Aurolife Pharma and 35 tentative approvals) from the US.
Stock of Aurobindo Pharma was trading 0.06 per cent lower at Rs 616.90 on BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Four-day market rally makes investors richer by Rs 8.48 lakh crore
Kotak Bank barred from onboarding customers online, issuing fresh credit cards
Reverse migration has begun, says FM Nirmala Sitharaman
Markets sustain winning streak — Sensex jumps over 560 points, Nifty tops 22,300-level
Sensex climbs 640 points, Nifty tops 22,300-level in early trade
MUST WATCH
Latest Additions
WATCH: 5 runaway military horses cause mayhem in London
FIR filed over BJP’s social media post allegedly promoting hatred and enmity: EC
Can’t control elections or pass directions on basis of suspicion: SC tells EVM critics
Amitabh Bachchan receives Lata Deenanath Mangeshkar Puraskar
Hubballi: Congress leader Randeep Surjewala visits Neha’s house, assures justice to family